Award of Share Options

RNS Number : 2330M

hVIVO plc

04 January 2019

 

hVIVO PLC

("hVIVO" or the "Company")

 

Award of Share Options

London, UK, 4 January 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that on 1st January 2019 it awarded the following options over ordinary shares of 5.0p each in the Company to Shelley Fraser:

Name	Position	Number of Share Options Awarded	Exercise price per Share	Date of Vesting	Percentage of issued ordinary share capital
Shelley Fraser	Finance Director (PDMR)	250,000	5.0p	1 January 2022	0.1%

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the persons discharging managerial responsibilities/persons closely associated
a)	Name	Shelley Fraser
2	Reason for the notification
a)	Position/ status	Finance Director (PDMR)
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over Ordinary Shares of 5 pence each ISIN: GB00B6ZM0X53
b)	Nature of the transaction	Award of options over ordinary shares in the Company
c)	Currency	GBP
d)	Price(s) and volume(s)	PDMR Exercise Price (p) Volume Shelley Fraser 5.0 250,000
e)	Aggregated information - Aggregated volume - Exercise price	Options over 250,000 ordinary shares 5.0p
f)	Date of the transaction	1st January 2019
g)	Place of the transaction	London Stock Exchange, AIM

For further information please contact:

hVIVO plc	[phone]
Trevor Phillips (Executive Chairman)
Fleur Wood (Director, Investor Relations)
Numis Securities Limited	[phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting	[phone]
Simon Conway / Victoria Foster Mitchell

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.

 

END

 

 

DSHUSVKRKKAARRR